Cancer Immunology and Immunotherapy
Read more
Are amplifying RNA vaccines the way forward for CAR-T-cell therapy?
Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required
Cancer Immunology and Immunotherapy
Read more
New immunotherapies are explored to improve the treatment of solid tumours
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Don't miss
-
Welcome session and Keynote Award 2021 lecture
8 December 2021, 12:30-13:00 -
Proffered Paper session I
9 December 2021, 09:00-10:30 -
Proffered Paper session II
10 December 2021, 09:00-10:30
EDITORIAL
Developing immunotherapies for mesothelioma
Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation
A new immunotherapy-based combination is promising in nasopharyngeal cancer
Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study
Can we further define patient groups who benefit from immunotherapy in advanced NSCLC?
Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups
Tumour mutational burden as a number – is it predictive enough?
Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
Survival benefits of pembrolizumab plus chemotherapy are confirmed in East-Asian patients with advanced NSCLC
Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status
ESMO IMMUNO-ONCOLOGY AWARD
Immunotherapy: from initial scepticism to the heart of cancer treatment
The ESMO Award for Immuno-Oncology 2021 is given to Prof. Wolf H. Fridman, whose research has made significant contributions to unveiling the prognostic and predictive role of the tumour microenvironment
How much is enough with immunotherapy?
For the recipient of the ESMO Award for Immuno-Oncology 2020, Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy
ESMO Immuno-Oncology Congress 2021: Prof. Thomas Powles on what you can expext from this event
All videosTopics
OPINIONS
Biomarkers for immunotherapy: where are we?
Andrew J.S. Furness
Which biomarkers and how many should we use to improve outcomes with immunotherapy?
Samra Turajlic
Trained immunity: a new promising oncology target?
Mihai Netea